A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy

Clinical Oncology

Volumn 8, Issue 5, 1996, Pages 297-307

  Hendry, J H ^a   Bentzen, S M ^b   Dale, R G ^c   Fowler, J F ^d   Wheldon, T E ^e   Jones, B ^f   Munro, A J ^g   Slevin, N J ^a   Robertson, A G ^h   Cowles, A ⁱ  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c CHARING CROSS HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^f CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^g ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^h BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

ⁱ ROYAL COLLEGE OF RADIOLOGISTS   (United Kingdom)

Author keywords

Fractionation; Gaps in treatment; Radiotherapy days missed; Time factors in radiotherapy; Treatment interruptions

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SQUAMOUS CELL CARCINOMA;

EID: 0029823807     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(05)80715-0     Document Type: Article

References (80)

1. Sambrook D. Clinical trial of a modified (split course) technique of X-ray therapy in malignant tumours. Clin Radiol 1968;36:369-72.
2. Parsons JT, Bova FJ, Million RR. A re-evaluation of split-course technique for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1980;6:1645-52.
3. Overgaard J, Hjelm-Hansen M, Johansen LV, et al. Comparison of conventional and split-course radiotherapy as a primary treatment in carcinoma of the larynx. Acta Oncol 1988;27:147-61.
4. Pajak TF, Laramore GE, Victor A, et al. Elapsed treatment days: A critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 1991;20:13-20.
5. Harari PM, Fowler JF. Idealized versus realized overall treatment times. Int J Radiat Oncol Biol Phys, 1994;29:209-11.
6. Bentzen SM, Overgaard M. Actual versus ideal treatment time in radiotherapy for head and neck cancer: Catching up with the gaps. Int J Radiat Oncol Biol Phys 1995;3:687-8.
7. Lindberg RD, Jones K, Garner HH, et al. Evaluation of unplanned interruptions in radiotherapy treatment schedules. Int J Radiat Oncol Biol Phys 1988;14:811-5.
8. Budihna M, Skrk J, Smid L, et al. Tumor cell repopulation in the rest interval of split-course radiation treatment. Strahlentherapie 1980;156:402-8.
9. Amdur RJ, Parsons JT, Mendenhall WM, et al. Split-course versus continuous course irradiation in the postoperative setting for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1989;17:279-85.
10. Van den Bogaert W, van der Leest A, Rijnders A, et al. Does tumour control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer? Radiother Oncol 1995;36:177-82.
11. Maciejewski B, Preuss-Bayer G, Trott K-R. The influence of the number of fractions and of overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx. Int J Radiat Oncol Biol Phys 1983;9:321-8.
12. Wang CC. Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes. Int J Radiat Oncol Biol Phys 1988;14:1143-6.
13. Bataini JP, Asselain B, Jaulerry C, et al. A multivariate primary tumour control analysis in 465 patients treated by radical radiotherapy for cancer of the tonsillar region: Clinical and treatment parameters as prognostic factors. Radiother Oncol 1989;14:265-77.
14. Mendenhall WM, Parsons JT, Stringer SP, et al. The T2 oral tongue carcinoma treated with radiotherapy: Analysis of local control and complications. Radiother Oncol 1989;16:275-81.
15. Taylor JMG, Withers HR, Mendenhall WM. Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. Radiother Oncol 1990;17:95-102.
16. Hoekstra CJM, Levendag PC, van Putten LJ. Squamous cell carcinoma of the supraglottic larynx without clinically detectable lymph node metastases: Problem of local relapse and influence of overall treatment time. Int J Radiat Oncol Biol Phys 1990;18:13-21.
17. Barton MB, Keane TJ, Galla T, et al. The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. Radiother Oncol 1992;24:137-43.
18. Robertson AG, Robertson C, Boyle P, et al. The effect of differing radiotherapeutic schedules on the response of glottic carcinoma of the larynx. Eur J Cancer 1993;4:501-10.
19. Robertson AG, Wheldon TE, Robertson C. Applying sound radiobiology principles to the management of carcinoma of the larynx. In: Tobias JS, Thomas PRM, editors. Current radiation oncology, vol. 2. London: Arnold, 1996:121-43.
20. Lanciano RM, Pajak TF, Martz K, et al. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A patterns-of-care study. Int J Radiat Oncol Biol Phys 1993;25:391-7.
21. Girinsky T, Rey A, Roche B, et al. Overall treatment time in advanced cervical carcinomas: A critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993;27:1051-6.
22. Petereit DG, Sarkaria JN, Chappel R, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995;32:1301-7.
23. Pedersen D, Bentzen SM, Overgaard J. Continuous or split-course combined external and intracavitary radiotherapy of locally advanced carcinoma of the uterine cervix. Acta Oncol 1994;33:547-55.
24. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-46.
25. Rezvani M, Fowler JF, Hopewell JW, et al. Sensitivity of human squamous carcinomas of the larynx to fractionated radiotherapy. Br J Radiol 1993;66:245-55.
26. Thames HD, Bentzen SM, Turesson I, et al. Time-dose factors in radiotherapy: A review of the human data. Radiother Oncol 1990;19:219-35.
27. Fowler JF. Apparent rates of proliferation of acutely responding normal tissue during radiotherapy of head and neck cancer. Int J Radiat Oncol Biol Phys 1991;21:1451-6.
28. Kaanders JH, van Daal WA, Hoogenvaad WJ, et al. Accelerated fractionation radiotherapy for laryngeal cancer: Acute and late toxicity. Int J Radiat Oncol Biol Phys 1992;24,497-503.
29. Benzten SM, Overgaard J. Clinical normal-tissue radiobiology. In: Tobias JS, Thomas PRM, editors. Current radiation oncology, vol. 2. London: Arnold, 1996:37-67.
30. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:457-67.
31. Bentzen SM. Time-dose relationships for human tumors: estimation from non-randomized studies. In: Beck-Bornholt HP, editor. Current topics in clinical radiobiology of tumours: medical radiology. Berlin: Springer-Verlag, 1993:11-26.
32. Fowler JF. Loss of local control with prolongation in radiotherapy. In: Kogelnik HD, editor. Progress in radio-oncology. Bologna, Italy: Monduzzi Editore, 1995:153-9.
33. Perez CA, Grigsby PW, Castro-Vita H, et al. Carcinoma of the uterine cervix: 1. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:1275-88.
34. Cox JD, Pajak TF, Asbell S, et al. Interruptions of high-dose radiation therapy decrease long-term survival of favourable patients with unresectable non-small cell carcinoma of the lung: Analysis of 1244 cases from three Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1993;27:493-8.
35. Holsti LR, Mantyla M. Split-course versus continuous radiotherapy: Analysis of a randomized trial from 1964 to 1967. Acta Oncol 1988;27:153-61.
36. Maciejewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991;21:163-70.
37. De Neve W, Lybeert MLM, Goor C, et al. Radiotherapy for T2 and T3 carcinoma of the bladder: The influence of overall treatment time. Radiother Oncol 1995;36:181-8.
38. Bentzen SM, Thames HD, Overgaard M. Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study. Radiother Oncol 1989;15:267-74.
39. Lai PP, Perez CA, Shapiro SJ, et al. Carcinoma of the prostate stage B and C: Lack of difference of duration of radiotherapy on tumour control and treatment morbidity. Int J Radiat Oncol Biol Phys 1990;19:561-8.
40. Lai PP, Pilepach MV, Krall JM, et al. The effect of overall time on the outcome of definitive radiotherapy for localised prostate carcinoma: The Radiation Therapy Oncology Group 75-06 and 77-06 experience. Int J Radiat Oncol Biol Phys 1991;21:925-3.
41. Andrev RJ, Parsons JT, Fitzgerald LT, et al. The effect of overall treatment time on local control in patients with adenocarcinoma of the prostate treated with radiation therapy. Int J Radiat Oncol Biol Phys 1990;19:1377-82.
42. Trott K, Kummermehr J. The time factor and repopulation in tumors and normal tissues. Semin Radiother Oncol 1993;3:115-25.
43. Hermann T, Jakubeck A, Trott KR. The importance of the timing of a split in radiotherapy of squamous cell carcinomas of the head and neck. Strahlenther Oncol 1994;130:545-9.
44. Skladowski K, Law MG, Maciejewski B, et al. Planned and unplanned gaps in radiotherapy: The importance of gap position and gap duration. Radiother Oncol 1994;30:109-20.
45. Slevin NJ, Hendry JH, Roberts SA, et al. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy. Radiother Oncol 1992;24:215-20.
46. Roberts SA, Hendry JH, Bewster AE, et al. The influence of radiotherapy treatment time on the control of laryngeal cancer: A direct analysis of data from two British Institute of Radiology trials to calculate the lag period and the time factor. Br J Radiol 1994;67:790-4.
47. Bentzen SM, Johansen LV, Overgaard, J, et al. Clinical radiobiology of squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys 1991;20:1197-206.
48. Bentzen SM, Thames HD. Clinical evidence for tumour clonogen regeneration: interpretations of the data. Radiother Oncol 1991;22:161-6.
49. Hendry JH, Roberts SA, Slevin NJ, et al. Influence of radiotherapy treatment time on control of laryngeal cancer: Comparisons between centres in Manchester, UK and Toronto Canada. Radiother Oncol 1994;31:14-22.
50. Fowler JF, Chappel R. Local control versus dose or overall time: From coefficients to percentages. Br J Radiol 1994;67:1108-12.
51. Maciejewski B, Withers HE, Taylor JMG, et al. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: Part 2. Normal tissue responses: Acute and late effects. Int J Radiat Oncol Biol Phys 1990;18:101-11.
52. Wheldon TE, Barrett A. Radiobiological rationale for compensation for gaps in radiotherapy regimes by post-gap acceleration of fractionation. Br J Radiol 1990;63:114-9
53. Yaes RJ. Some common causes of treatment prolongation. Int J Radiat Oncol Biol Phys 1995;31:686-7.
54. Ang KK, Jian GL, Guttenberger G, et al. Impact of spinal cord repair kinetics on the practice of altered fractionation schedules. Radiother Oncol 1992;25:287-94.
55. Millar WT, Canney PA. The derivation and application of equations describing the effects of fractionated protracted irradiation, based on multiple and incomplete repair processes: Part 2. Analysis of mouse lung data. Int J Radiat Biol 1993;64:293-303.
56. Millar WT, van den Aardweg GJMJ, Hopewell JW, et al. Repair kinetics in pig epidermis: An analysis based on two separate rates of repair. Int J Radiat Biol 1996;69:123-40.
57. Millar WT, Jen YM, Hendry JH, et al. Two components of repair in irradiated kidney colony-forming cells. Int J Radiat Biol 1994;66:289-96.
58. Hendry JH, Jen Y-M. The time factor for late reactions in radiotherapy: Repopulation or intracellular repair? Recent Results Cancer Res 1993;130:17-26.
59. Bentzen SM, Ruifrok ACC, Thames HD. Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: Clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. Radiother Oncol 1996;38:89-101.
60. Turesson I, Thames HD. Repair capacity and kinetics of human skin during fractionated radiotherapy: Erythema, desquamation, and telangiectasia after 3 and 5 years' follow up. Radiother Oncol 1989;15:169-88.
61. Nyman J, Turesson I. Does the interval between fractions matter in the range of 4-8 h in radiotherapy? A study of acute and late human skin reactions. Radiother Oncol 1995;34:171-8.
62. Bentzen SM, Thames HD. Dose-response relationships for late radiation effects in the head and neck. (Regarding the analysis of the RTOG 8313 trial, Fu et al. IJROBP 32: 577-588, 1995.) Int J Radiat Oncol Biol Phys 1996;34:523-4.
63. Slevin NJ, Vasanthan S, Dougal M. Relative clinical influence of tumour dose versus dose per fraction on the occurrence of late normal tissue morbidity following larynx radiotherapy. Int J Radiat Oncol Biol Phys. 1993;25:22-8.
64. Mijnheer BJ, Batterman JJ, Wambersie A. What degree of accuracy is required and can be achieved in photon and neutron therapy? Radiother Oncol 1987;8:237-52.
65. Thames HD, Schultheiss TE, Hendry JH, et al. Can modest escalations of dose be detected as increased tumour control? Int J Radiat Oncol Biol Phys 1991;22:241-6.
66. Hendry JH. Treatment acceleration in radiotherapy: The relative time factors and dose-response slopes for tumours and normal tissues. Radiother Oncol 1992;25:308-12.
67. Bentzen SM. Radiobiological considerations in the design of clinical trials. Radiother Oncol 1994;32:1-11.
68. Stewart JG, Jackson AW. The steepness of the dose-response curve both for tumour cure and normal tissue injury. Laryngoscope 1975;85:1107-11.
69. Roberts SA, Hendry JH. The delay before onset of accelerated tumour cell repopulation during radiotherapy: A direct maximum-likelihood analysis of a collection of worldwide tumour-control data. Radiother Oncol 1993;29:69-74.
70. Bentzen SM, Turesson I, Thames HD. Fractionation sensitivity and latency of telangiectasia after postmastectomy radiotherapy: A graded-response analysis. Radiother Oncol 1990;18:95-106.
71. Bentzen SM, Overgaard M. Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. Radiother Oncol 1991;20:159-65.
72. Hendry JH. Response of human organs to single (or fractionated equivalent) doses of irradiation. Int J Radiat Biol 1989;56:691-700.
73. Dale RG, Sinclair JA. A proposed figure of merit for the assessment of unscheduled treatment interruptions. Br J Radiol 1994;67:1001-7.
74. Bentzen SM. Steepness of the clinical dose-control curve and variation in the in vitro radiosensitivity of head and neck squamous cell carcinoma. Int J Radiat Biol 1992;61: 417-23.
75. Fyles A, Keane TJ, Barton M, et al. The effect of treatment duration on the local control of cervix cancer. Radiother Oncol 1992;25:273-9.
76. Tan LT, Jones B, Green JA, et al. Treatment of carcinomas of the uterine cervix which remain bulky after initial external beam radiotherapy: A pilot study using integrated cytotoxic chemotherapy prior to brachytherapy. Br J Radiol 1995;69:165-71.
77. Jones B, Tan LT, Blake PR, et al. Results of a questionnaire regarding the practice of radiotherapy for carcinoma of the cervix in the UK. Br J Radiol 1994;67:1226-30
78. Tan LT, Jones B, Frestone G, et al. Case report: Low dose rate and high dose rate intracavitary brachytherapy in a patient with carcinoma of the cervix. Br J Radiol 1996; 69:84-6.
79. Brahme A. Dosimetric precision requirements in radiation therapy. Acta Radiol Oncol 1984;23:379-91.
80. Fowler J. The linear quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-94.